IN2015KN00007A - - Google Patents
Info
- Publication number
- IN2015KN00007A IN2015KN00007A IN7KON2015A IN2015KN00007A IN 2015KN00007 A IN2015KN00007 A IN 2015KN00007A IN 7KON2015 A IN7KON2015 A IN 7KON2015A IN 2015KN00007 A IN2015KN00007 A IN 2015KN00007A
- Authority
- IN
- India
- Prior art keywords
- tau
- antibodies
- methods
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Abstract
This invention relates to antibodies to tau and methods of use thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261667515P | 2012-07-03 | 2012-07-03 | |
US201261694989P | 2012-08-30 | 2012-08-30 | |
PCT/US2013/049333 WO2014008404A1 (en) | 2012-07-03 | 2013-07-03 | Antibodies to tau |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015KN00007A true IN2015KN00007A (en) | 2015-07-31 |
Family
ID=49882495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN7KON2015 IN2015KN00007A (en) | 2012-07-03 | 2013-07-03 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9834596B2 (en) |
EP (2) | EP2870176A4 (en) |
JP (3) | JP6345655B2 (en) |
KR (3) | KR20200013072A (en) |
CN (2) | CN104781278B (en) |
AU (3) | AU2013286680B2 (en) |
CA (1) | CA2877397A1 (en) |
HK (1) | HK1209768A1 (en) |
IL (3) | IL236409B (en) |
IN (1) | IN2015KN00007A (en) |
MX (2) | MX359555B (en) |
MY (1) | MY171473A (en) |
NZ (2) | NZ703423A (en) |
RU (2) | RU2668159C2 (en) |
SG (3) | SG10201708959WA (en) |
WO (1) | WO2014008404A1 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104781278B (en) | 2012-07-03 | 2018-06-12 | 华盛顿大学 | For the antibody of TAU |
MX359817B (en) | 2012-08-16 | 2018-10-11 | Ipierian Inc | Methods of treating a tauopathy. |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
AU2014248515B2 (en) * | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
CN107074935B (en) * | 2014-06-26 | 2021-08-03 | 扬森疫苗与预防公司 | Antibodies and antigen binding fragments that specifically bind to microtubule-associated protein TAU |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TWI664190B (en) * | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | Humanized anti-tau antibodies |
KR102502356B1 (en) | 2014-09-30 | 2023-02-21 | 워싱턴 유니버시티 | Tau kinetic measurements |
MA41451A (en) * | 2015-02-04 | 2017-12-12 | Univ Washington | ANTI-TAU CONSTRUCTIONS |
AR103713A1 (en) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | ANTIBODIES AGAINST TAU AND ITS USES |
CN107849124B (en) | 2015-06-05 | 2021-09-24 | 基因泰克公司 | anti-TAU antibodies and methods of use |
US10287343B2 (en) * | 2015-07-06 | 2019-05-14 | Ucb Biopharma Sprl | Tau-binding antibodies |
MA41669A1 (en) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Antibodies binding to tau |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
PT3334761T (en) * | 2015-08-13 | 2023-08-17 | Univ New York | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
CN105158483A (en) * | 2015-09-16 | 2015-12-16 | 北京九强生物技术股份有限公司 | Quantitative determination kit for hypersensitivity of Troponin I and detection method |
CN109415434B (en) | 2016-05-02 | 2022-12-30 | 普罗塞纳生物科学有限公司 | Antibodies recognizing TAU |
KR102471787B1 (en) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | Tau recognition antibody |
ES2933491T3 (en) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | tau immunotherapy |
MY197836A (en) | 2016-07-12 | 2023-07-20 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
KR102593669B1 (en) | 2016-11-15 | 2023-10-25 | 하. 룬드벡 아크티에셀스카브 | Agents, uses and methods for the treatment of synucleinopathies |
AU2017373884A1 (en) | 2016-12-07 | 2019-05-30 | Ac Immune Sa | Anti-tau antibodies and methods of their use |
CR20230163A (en) | 2016-12-07 | 2023-07-06 | Genentech Inc | Anti-tau antibodies and methods of use |
CN106749658B (en) * | 2016-12-15 | 2019-11-12 | 北京师范大学 | Inhibit the anitibody type molecular chaperones of Tau albumen aggregation |
MA47019A (en) | 2016-12-16 | 2021-04-21 | H Lundbeck As | AGENTS, USES AND METHODS |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
EP3583123A1 (en) * | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
EP3592387A4 (en) * | 2017-03-09 | 2021-03-31 | The Board of Trustees of the Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
CA3061516A1 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
TWI750419B (en) * | 2017-10-16 | 2021-12-21 | 日商衛材R&D企管股份有限公司 | Anti-tau antibodies and uses thereof |
CA3094934A1 (en) | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
US11629175B2 (en) | 2018-04-27 | 2023-04-18 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for preparing PHFS-like Tau aggregates |
JP2021530552A (en) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | Combination therapy |
CN109613242A (en) * | 2018-11-01 | 2019-04-12 | 深圳天辰医疗科技有限公司 | A kind of creatine kinase isozyme detection kit and preparation method thereof |
WO2020180819A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
EP3769090B1 (en) | 2019-03-18 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation |
KR20210141522A (en) | 2019-03-18 | 2021-11-23 | 리제너론 파마슈티칼스 인코포레이티드 | CRISPR/Cas Screening Platform to Identify Genetic Modifiers of Tau Seeding or Aggregation |
CN110055280A (en) * | 2019-03-19 | 2019-07-26 | 深圳大学 | A kind of cell line and its construction method and application of stable expression mCherry-tau |
GB2600599A (en) * | 2019-07-15 | 2022-05-04 | Adel Inc | Anti-tau antibody and use of same |
CA3156678A1 (en) | 2019-10-09 | 2021-04-15 | Bluerock Therapeutics Lp | Cells with sustained transgene expression |
EP4069734A1 (en) * | 2019-12-04 | 2022-10-12 | AC Immune SA | Novel molecules for therapy and diagnosis |
EP4241088A1 (en) * | 2020-11-09 | 2023-09-13 | Meso Scale Technologies, LLC | Methods and kits for detecting tau |
WO2022144406A1 (en) | 2020-12-29 | 2022-07-07 | Neurimmune Ag | Human anti-tau antibodies |
IL307170A (en) | 2021-03-26 | 2023-11-01 | Janssen Biotech Inc | Anti-tau antibodies and uses thereof |
AU2022246275A1 (en) | 2021-03-26 | 2023-11-09 | Janssen Biotech, Inc. | Humanized antibodies against paired helical filament tau and uses thereof |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI884505A (en) | 1987-10-02 | 1989-04-03 | Du Pont | IMMUNOANALYS, I VILKEN ANVAENDS IGG-UPPSNAPPANDE ANTIKROPPAR OCH DETEKTERINGSSYSTEM FOER FLERA MONOCLONALA ANTIKROPPAR. |
EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
US5733734A (en) | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
JP3909084B2 (en) | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | Monoclonal antibody against microtubule-associated protein tau |
ATE438716T1 (en) | 1991-12-06 | 2009-08-15 | Max Planck Gesellschaft | USE OF PROTEIN KINASES TO DIAGNOSE AND TREAT ALZHEIMER'S DISEASE |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
JPH06239899A (en) | 1993-02-12 | 1994-08-30 | Teijin Ltd | Antibody for human tau protein and determination of human tau protein in body fluid utilizing the same |
AU710952B2 (en) | 1994-07-29 | 1999-09-30 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
WO1997034145A1 (en) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Antiphosphorylated tau protein antibody and method for detecting alzheimer's disease with the use of the same |
WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
US6797478B1 (en) | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
RU2238947C2 (en) * | 1998-07-14 | 2004-10-27 | Янссен Фармацевтика Н.В. | Human neurotrophic growth factor (enovin), isolated nucleic acid molecule encoding its, vector (variants), pharmaceutical composition (variants), antibody, method for detection of growth factor, set, method for identification of agonist or antagonist (variants) |
CA2340433A1 (en) | 1998-09-08 | 2000-03-16 | Innogenetics N.V. | Tau as a marker for early cns damage |
US6495376B1 (en) * | 1999-02-18 | 2002-12-17 | Beth Israel Deaconess Medical Center | Methods and compositions for regulating protein-protein interactions |
US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
AT500379B8 (en) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | TAU PROTEINS |
AR035119A1 (en) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | ANTI-HTNFSF13B HUMAN ANTI-BODIES |
WO2003057881A1 (en) | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
HUE030806T2 (en) | 2002-05-02 | 2017-05-29 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
DK1521831T3 (en) | 2002-07-12 | 2008-06-30 | Axon Neuroscience | Transgenic animals expressing truncated Alzheimer's tau protein |
EP1535930B1 (en) | 2002-08-14 | 2010-10-06 | Mitsubishi Chemical Medience Corporation | Antibody specific to central nervous system tau protein |
FI20030652A0 (en) | 2003-04-30 | 2003-04-30 | Susann Eriksson | Improved immune determination |
CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
WO2006088281A1 (en) | 2005-02-19 | 2006-08-24 | Peoplebio, Inc. | Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides |
US20070134724A1 (en) | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
ES2321996B1 (en) | 2006-01-26 | 2010-03-05 | Consejo Superior Investig. Cientificas | USE OF COMPOUNDS THAT JOIN THE DOMAIN OF UNION TO TAU MICROTUBLES IN THE DEVELOPMENT OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THE TREATMENT OF TAUOPATIAS. |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
CN102076339A (en) | 2008-04-24 | 2011-05-25 | 百时美施贵宝公司 | Use of epothelone d in treating tau-associated diseases including alzheimer's disease |
CN101307108B (en) | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | Anti-phosphorylation Tau protein antibody use for detecting AD sign abnormal phosphation Tau protein level |
DK2365802T3 (en) * | 2008-11-11 | 2017-11-13 | Univ Texas | RAPAMYCINE MICROCAPLES AND USE FOR CANCER TREATMENT |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
WO2010096751A1 (en) | 2009-02-23 | 2010-08-26 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta |
UA107571C2 (en) | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
US8409584B2 (en) | 2009-05-05 | 2013-04-02 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
CA3120504A1 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
SG177637A1 (en) * | 2009-07-30 | 2012-03-29 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
JP6124591B2 (en) | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | Antibodies that bind to tau oligomers |
US20130022982A1 (en) * | 2009-09-14 | 2013-01-24 | Kevin Ka-Wang Wang | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
EP2480891B1 (en) | 2009-09-24 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction |
US20130095492A1 (en) | 2010-03-05 | 2013-04-18 | Albert Einstein College Of Medicine Of Yeshiva University | Method of detecting tau protein and tau fragments in serum |
AU2013205313B2 (en) | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
TW201216985A (en) * | 2010-10-07 | 2012-05-01 | Ac Immune Sa | Pharmaceutical composition |
JP2014503178A (en) * | 2010-10-11 | 2014-02-13 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | Human anti-tau antibody |
US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
US20120321594A1 (en) | 2011-05-06 | 2012-12-20 | New York University | Methods of controlling axon or dendrite development of neuronal cells |
US9506051B2 (en) | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
US9926353B2 (en) | 2011-07-19 | 2018-03-27 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
SG10201912964PA (en) | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
EP2764022B9 (en) | 2011-10-07 | 2017-02-22 | AC Immune S.A. | Phosphospecific antibodies recognising tau |
US20140294724A1 (en) | 2011-10-24 | 2014-10-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
JP6306513B2 (en) | 2011-12-20 | 2018-04-04 | ヤンセン バイオテツク,インコーポレーテツド | Anti-PHF-tau antibody and use thereof |
MX356800B (en) | 2012-04-05 | 2018-06-13 | Ac Immune Sa | Humanized tau antibody. |
WO2013177104A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment for tauopathies |
DK2857039T3 (en) | 2012-05-31 | 2019-12-16 | Univ Osaka City | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT AGAINST DEMENS |
CN104781278B (en) | 2012-07-03 | 2018-06-12 | 华盛顿大学 | For the antibody of TAU |
MX359817B (en) | 2012-08-16 | 2018-10-11 | Ipierian Inc | Methods of treating a tauopathy. |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
JP2015527369A (en) | 2012-08-21 | 2015-09-17 | インスティテュート フォー モレキュラー メディシン, インコーポレイテッド | Compositions and methods relating to diseases associated with deposition of amyloid, tau and α-synuclein |
EP2906596B1 (en) | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
WO2014089104A1 (en) | 2012-12-03 | 2014-06-12 | Washington University | Method for detection of aggregates in biological samples |
US8921150B2 (en) | 2012-12-06 | 2014-12-30 | Taiwan Semiconductor Manufacturing Co., Ltd. | Process to achieve contact protrusion for single damascene via |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
WO2014096321A1 (en) | 2012-12-21 | 2014-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies |
EA035932B1 (en) | 2012-12-21 | 2020-09-02 | Байоджен Ма Инк. | Human anti-tau antibodies |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
WO2014159244A2 (en) | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
MX2015012872A (en) | 2013-03-15 | 2016-02-03 | Ac Immune Sa | Anti-tau antibodies and methods of use. |
CN105283196B (en) | 2013-03-15 | 2018-10-12 | 贝丝以色列女执事医疗中心 | For generate and using conformation-specific antibody method and composition |
TWI664190B (en) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | Humanized anti-tau antibodies |
-
2013
- 2013-07-03 CN CN201380045706.3A patent/CN104781278B/en active Active
- 2013-07-03 NZ NZ703423A patent/NZ703423A/en not_active IP Right Cessation
- 2013-07-03 US US14/412,309 patent/US9834596B2/en active Active
- 2013-07-03 SG SG10201708959WA patent/SG10201708959WA/en unknown
- 2013-07-03 RU RU2015103228A patent/RU2668159C2/en active
- 2013-07-03 AU AU2013286680A patent/AU2013286680B2/en active Active
- 2013-07-03 SG SG10201913370PA patent/SG10201913370PA/en unknown
- 2013-07-03 KR KR1020207002242A patent/KR20200013072A/en not_active Application Discontinuation
- 2013-07-03 KR KR1020207033554A patent/KR102494798B1/en active IP Right Grant
- 2013-07-03 CA CA2877397A patent/CA2877397A1/en not_active Abandoned
- 2013-07-03 RU RU2018132044A patent/RU2018132044A/en unknown
- 2013-07-03 KR KR20157002867A patent/KR20150036346A/en active IP Right Grant
- 2013-07-03 EP EP13813988.6A patent/EP2870176A4/en not_active Withdrawn
- 2013-07-03 WO PCT/US2013/049333 patent/WO2014008404A1/en active Application Filing
- 2013-07-03 CN CN201810507442.3A patent/CN108623682A/en active Pending
- 2013-07-03 MY MYPI2014704038A patent/MY171473A/en unknown
- 2013-07-03 MX MX2014016024A patent/MX359555B/en active IP Right Grant
- 2013-07-03 SG SG11201408626YA patent/SG11201408626YA/en unknown
- 2013-07-03 IN IN7KON2015 patent/IN2015KN00007A/en unknown
- 2013-07-03 NZ NZ739622A patent/NZ739622A/en not_active IP Right Cessation
- 2013-07-03 EP EP20199802.8A patent/EP3838921A3/en not_active Withdrawn
- 2013-07-03 JP JP2015520685A patent/JP6345655B2/en not_active Expired - Fee Related
-
2014
- 2014-12-19 MX MX2022000026A patent/MX2022000026A/en unknown
- 2014-12-23 IL IL236409A patent/IL236409B/en active IP Right Grant
-
2015
- 2015-10-28 HK HK15110657.6A patent/HK1209768A1/en unknown
-
2017
- 2017-06-02 US US15/612,695 patent/US20180037641A1/en not_active Abandoned
-
2018
- 2018-05-23 JP JP2018098889A patent/JP2018184398A/en active Pending
- 2018-09-17 AU AU2018229564A patent/AU2018229564A1/en not_active Abandoned
-
2020
- 2020-04-09 JP JP2020070416A patent/JP2020125310A/en active Pending
- 2020-08-28 AU AU2020223765A patent/AU2020223765A1/en not_active Abandoned
- 2020-09-29 IL IL277643A patent/IL277643A/en unknown
-
2021
- 2021-12-21 IL IL289241A patent/IL289241A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000026A (en) | Antibodies to tau. | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
MX342240B (en) | Anti-fgfr4 antibodies and methods of use. | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
IL245237A0 (en) | Novel anti-claudin antibodies and methods of use | |
MX2014004022A (en) | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE. | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX2014002053A (en) | Anti-mcsp antibodies. | |
MX2015012326A (en) | Anti-crth2 antibodies and their use. | |
MX2015013901A (en) | Anti-il-4 antibodies and bispecific antibodies and uses thereof. | |
IN2015DN00127A (en) | ||
EP2970508A4 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
IL245946A0 (en) | Novel anti-dpep3 antibodies and methods of use | |
IN2014DN08721A (en) | ||
MX354303B (en) | Anti-biotin antibodies and methods of use. | |
IN2013MU00848A (en) | ||
IN2014DN09450A (en) | ||
MX2014014381A (en) | Anti-theophylline antibodies and methods of use. | |
MX2014014443A (en) | Tlr3 binding agents. | |
MX2015010789A (en) | Anti-mcsp antibodies. | |
NZ743971A (en) | Antibodies to tau |